|
| Press Releases |
|
 |
|
| Tuesday, August 25, 2020 |
|
|
Eisai to Present Latest Data of Lemborexant at 34th Annual Sleep Meeting (SLEEP2020) |
| Eisai Co., Ltd. announced today that a total of 10 presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGOTM CIV) will be given at the 34th annual meeting of the Associated Professional Sleep Societies (SLEEP 2020), to be held virtually from August 27 to 30, 2020. more info >> |
|
| Friday, July 31, 2020 |
|
|
Eisai: Application for Additional Indication of Anti Cancer Agent Lenvima for Unresectable Thymic Carcinoma Submitted in Japan |
| In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma. more info >> |
|
| Wednesday, July 22, 2020 |
|
|
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020 |
| Eisai Co., Ltd. announced today that the company will conduct a total of 9 presentations, including the latest data of the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401, at the Alzheimer's Association International Conference (AAIC) to be held virtually from July 27 to 31, 2020. more info >> |
|
| Monday, July 20, 2020 |
|
|
Eisai: Smartphone App for Vital Signs Measurement of Patients With the Novel Coronavirus Infection Experimental Study Project Adopted as AMED Project |
| Allm Inc., Tokyo Medical and Dental University and Eisai Co., Ltd. announced that their jointly submitted study and development project has been selected by the Japan Agency for Medical Research and Development (AMED). more info >> |
|
| Tuesday, July 14, 2020 |
|
|
Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease |
| The AHEAD 3-45 will be conducted in the US, Japan, Canada, Australia, Singapore, and Europe. more info >> |
|
| Monday, July 13, 2020 |
|
|
Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded |
| Eisai Co., Ltd. announced today that it has entered into an industry-academia-government joint research agreement with four universities in Japan concerning the "Industrialization of Japan-originated Toll-like receptor research by Academia-Industry collaborating All-Japan system: Creation of new drug for SLE treatment", which is a research project with Eisai as the representative research organization. more info >> |
|
| Thursday, July 9, 2020 |
|
|
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease |
| Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab, an investigational treatment for Alzheimer's disease. more info >> |
|
|
Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA. more info >> |
|
| Wednesday, July 8, 2020 |
|
|
Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong |
| Eisai Co., Ltd. announced today that the new drug application for approval of its in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, has been accepted by the Hong Kong Department of Health. more info >> |
|
|
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma |
| Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for the EZH2 inhibitor tazemetostat hydrobromide (generic name, development code: E7438, "tazemetostat") for EZH2 gene mutation-positive follicular lymphoma. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
International Medical and Healthcare Week Highlights Hong Kong's Strengths in Medical and Innovation
May 15, 2025 20:14 HKT/SGT
|
|
|
Global Sports Brand U.S. Polo Assn. Launches Menswear in Argentina
May 15, 2025 19:00 HKT/SGT
|
|
|
HODL 2025 opens in Dubai, advancing the Emirates' position as a global financial innovation hub
May 15, 2025 13:33 HKT/SGT
|
|
|
Honda and Quemix Co-develop a New, World's First Quantum State Readout Technology
May 15, 2025 13:37 JST
|
|
|
Mitsubishi Electric Building Solutions Launches a New Projection-type Hall Lantern for Overseas Markets 
May 15, 2025 11:00 JST
|
|
|
Hola Prime and Pro Basketball Player Karl-Anthony Towns Team up for 'Speed is Success' Campaign, Redefining Prop Trading
May 14, 2025 22:20 HKT/SGT
|
|
|
Business delegation concludes Middle East mission in Kuwait
May 14, 2025 21:37 HKT/SGT
|
|
|
Quotient Capital's Strategic Outlook for 2025
May 14, 2025 19:45 HKT/SGT
|
|
|
Staying Ahead in the Digital Era as AI Takes Full Center Stage at InfoComm Asia 2025 -- Visitor Registration Opens
May 14, 2025 18:29 HKT/SGT
|
|
|
MHI Starts Operation of New CO2 Capture Pilot Plant at KEPCO's Himeji No.2 Power Station
May 14, 2025 16:50 JST
|
|
|
Southeast Asian stem cell leader Medeze launches voluntary conditional cash partial offer for 10% stake in SGX-listed Cordlife Group Limited
May 14, 2025 15:00 HKT/SGT
|
|
|
Making Anime More Interesting and Taking it into the Future, Launch of Three New Projects
May 14, 2025 11:00 JST
|
|
|
African Mining Giant Intends to List in Hong Kong to Build West African Gold Leader
May 13, 2025 19:41 HKT/SGT
|
|
|
OMP's Unison Planning Achieves SAP(R) Certified Integration with RISE with SAP S/4HANA(R) Cloud
May 13, 2025 19:00 HKT/SGT
|
|
|
Widespread Use Of Illicit Streaming Devices In Taiwan Poses Potential National Cybersecurity Threat, New Research Finds
May 13, 2025 17:05 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
